From: Health and economic impact of rotavirus vaccination in GAVI-eligible countries
 |  |  | Financial costsa | |||
---|---|---|---|---|---|---|
No | Scale-up scenarios | No. of children vaccinated | Global society perspective (Total vaccination program costs) | GAVI Alliance perspective (Vaccine cost support) | Local government perspective (not including medical cost savings)b | Local government perspective (including medical cost savings)b |
 |  | (in million) | (US$, million) | (US$, million) | (US$, million) | (US$, million) |
1 | Base-case rollout scenario (Table 2) | Â | Â | Â | Â | Â |
 | Vaccine efficacy based on the SAGE approach |  |  |  |  |  |
 | Vaccine immunity waning (14% annually) | 281.8 | 5,879 | 4,079 | 1,800 | 1,714 |
2 | Base-case rollout scenario (Table 2) | Â | Â | Â | Â | Â |
 | Vaccine efficacy based on the SAGE approach |  |  |  |  |  |
 | No vaccine immunity waning | 281.8 | 5,879 | 4,079 | 1,800 | 1,707 |
3 | Base-case rollout scenario (Table 2) | Â | Â | Â | Â | Â |
 | Vaccine efficacy adjusted for serotype distribution |  |  |  |  |  |
 | Vaccine immunity waning (14% annually) | 281.8 | 5,879 | 4,079 | 1,800 | 1,695 |
4c | Base-case rollout scenario (Table 2) | Â | Â | Â | Â | Â |
 | Vaccine efficacy adjusted for serotype distribution |  |  |  |  |  |
 | No vaccine immunity waning | 281.8 | 5,879 | 4,079 | 1,800 | 1,686 |
5 | (Modified) Wolfson et al. scenario [30] | Â | Â | Â | Â | Â |
 | Vaccine efficacy based on the SAGE approach |  |  |  |  |  |
 | No vaccine immunity waning | 410.5 | 8,573 | 5,943 | 2,630 | 2,472 |
6 | (Modified) Wolfson et al. scenario [30] | Â | Â | Â | Â | Â |
 | Vaccine efficacy adjusted for serotype distribution |  |  |  |  |  |
 | No vaccine immunity waning | 410.5 | 8,573 | 5,943 | 2,630 | 2,414 |
7 | A flat coverage of 70% | Â | Â | Â | Â | Â |
 | Vaccine efficacy based on the SAGE approach |  |  |  |  |  |
 | No vaccine immunity waning | 537.0 | 11,222 | 7,785 | 3,437 | 3,236 |
8 | A flat coverage of 70% | Â | Â | Â | Â | Â |
 | Vaccine efficacy adjusted for serotype distribution |  |  |  |  |  |
 | No vaccine immunity waning | 537.0 | 11,222 | 7,785 | 3,437 | 3,170 |